Literature DB >> 8093681

Effects of modafinil on symptomatology of human narcolepsy.

D B Boivin1, J Montplaisir, D Petit, C Lambert, S Lubin.   

Abstract

We studied the effects of modafinil, a putative central alpha-1 agonist, on the excessive daytime sleepiness (EDS) of 10 narcoleptic patients while using a double-blind design and objective measurements of vigilance. There were two treatment periods, in which either modafinil or placebo was used; each lasted four weeks and was preceded by a 2-week "run-in" period and separated by a 2-week "wash-out" period. The effects of treatment on EDS were evaluated by daily home questionnaires and a psychomotor performance test, the Four Choice Reaction Time Test (FCRTT). Modafinil reduced the daily number of sleep attacks significantly, and markedly improved performances during the FCRTT. Results of this study suggest that modafinil is effective in treating EDS in narcolepsy, and that noradrenergic mechanisms could be involved in the physiopathology of EDS in that disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093681     DOI: 10.1097/00002826-199302000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

1.  Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission.

Authors:  C Sebban; X Q Zhang; B Tesolin-Decros; M J Millan; M Spedding
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil.

Authors:  L H Gold; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

Review 3.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

4.  Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.

Authors:  Michael J Thorpy; Jonathan R L Schwartz; Ruzica Kovacevic-Ristanovic; Roza Hayduk
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

5.  EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

Authors:  Michael T Saletu; Peter Anderer; Gerda M Saletu-Zyhlarz; Magdalena Mandl; Oliver Arnold; Dorothea Nosiska; Josef Zeitlhofer; Bernd Saletu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 6.  [Advances in treatment of narcolepsy].

Authors:  Qinglin Xu; Guodong Lou; Tiantian Wang; Lisan Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-08-25

7.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

Authors:  K J McClellan; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 8.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial.

Authors:  Florien W Boele; Linda Douw; Marjolein de Groot; Hinke F van Thuijl; Wilmy Cleijne; Jan J Heimans; Martin J B Taphoorn; Jaap C Reijneveld; Martin Klein
Journal:  Neuro Oncol       Date:  2013-08-07       Impact factor: 12.300

10.  High resolution mapping of modafinil induced changes in glutamate level in rat brain.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Kavindra Nath; Gaurav Verma; Ravi Prakash Reddy Nanga; Hari Hariharan; John A Detre; Neill Epperson; Ravinder Reddy
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.